Global Chronic Kidney Disease (CKD) Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Erythropoietin Stimulating Agents, Calcium Channel Blockers, Phosphate Binders, ACE Inhibitors, and Others.

By Route Of Administration;

Oral, Subcutaneous, and Intravenous.

By Distribution Channel;

Hospitals, Retail pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn425830367 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Chronic Kidney Disease (CKD) Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Chronic Kidney Disease (CKD) Drugs Market was valued at USD 14,558.53 million. The size of this market is expected to increase to USD 18,273.42 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.3%.

The Chronic Kidney Disease (CKD) Drugs Market is poised for substantial growth, driven by increasing demand from hospitals and specialty clinics worldwide. This growth is expected to be exponential, with a remarkable Compound Annual Growth Rate (CAGR) during the forecast period. CKD drugs are witnessing rising demand due to the escalating prevalence of chronic kidney disease and the expanding applications in healthcare facilities. The market report provides insights into lucrative opportunities at both the global and country levels. It encompasses a thorough analysis of quantitative and qualitative data, offering forecasts. Factors considered include product pricing, market penetration, country GDP, market dynamics, end-application industries, major players, consumer behavior, and socio-political scenarios. The report is segmented to provide a detailed market analysis from various perspectives, including end-use industry and product or service type.

Key sections of the report include market segments, market outlook, competitive landscape, and company profiles. The market segments offer insights into different aspects such as end-use industry and product or service type, allowing for targeted marketing activities. The market outlook section delves into market evolution, growth drivers, restraints, opportunities, and challenges. It includes frameworks like Porter’s 5 Forces, macroeconomic analysis, value chain analysis, and pricing analysis. These factors collectively shape the market landscape, influencing current dynamics and future projections. Internal factors such as drivers and restraints, as well as external factors like opportunities and challenges, are thoroughly explored.

The market outlook section highlights trends driving new business development and investment opportunities. With chronic kidney disease becoming a growing concern globally, the demand for effective treatments is on the rise. Hospitals and specialty clinics are increasingly relying on CKD drugs to manage and treat patients with kidney-related ailments. This trend is further fueled by advancements in medical research and technology, leading to the development of innovative therapies. Additionally, favorable reimbursement policies and government initiatives aimed at improving healthcare infrastructure contribute to market growth.

The Chronic Kidney Disease Drugs Market is expected to witness significant expansion driven by increasing demand from healthcare facilities globally. The comprehensive market report provides valuable insights into market dynamics, trends, and opportunities, guiding stakeholders in making informed decisions and capitalizing on emerging prospects in the CKD drugs market.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Route Of Administration
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Chronic Kidney Disease (CKD) Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Developments in Treatment Options

        2. Growing Healthcare Expenditure

        3. Dietary Patterns and Lifestyle Shifts

      2. Restraints
        1. Restricted therapy Options

        2. Exorbitant Treatment Costs

        3. Generic Competition

      3. Opportunities
        1. Increasing Disease Burden

        2. Favorable Regulatory Environment

        3. Growing Demand for Disease Management

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Erythropoietin Stimulating Agents
      2. Calcium Channel Blockers
      3. Phosphate Binders
      4. ACE Inhibitors
      5. Others
    2. Global Chronic Kidney Disease (CKD) Drugs Market, By Route Of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Subcutaneous
      3. Intravenous
    3. Global Chronic Kidney Disease (CKD) Drugs Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Retail pharmacies
      3. Online Pharmacies
    4. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America

        1. United States

        2. Canada

      2. Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Nordic

        7. Benelux

        8. Rest of Europe

      3. Asia Pacific

        1. Japan

        2. China

        3. India

        4. Australia & New Zealand

        5. South Korea

        6. ASEAN (Association of South East Asian Countries)

        7. Rest of Asia Pacific

      4. Middle East & Africa

        1. GCC

        2. Israel

        3. South Africa

        4. Rest of Middle East & Africa

      5. Latin America

        1. Brazil

        2. Mexico

        3. Argentina

        4. Rest of Latin America

  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie Inc

      2. Akebia Therapeutics Inc

      3. Amgen Inc.

      4. AstraZeneca Plc

      5. Bayer AG

      6. Biogen Inc

      7. Boehringer Ingelheim International GmbH

      8. Cara Therapeutics Inc

      9. Eli Lilly and Co

      10. F. Hoffmann La Roche Ltd

      11. FibroGen Inc

      12. Horizon Therapeutics Plc

      13. Johnson and Johnson

      14. Kissei Pharmaceutical Co. Ltd

      15. Novartis AG

  7. Analyst Views
  8. Future Outlook of the Market